文献速递胸部肿瘤

磨玻璃影为主型肺腺癌纵隔淋巴结清扫的III期研究

Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity-Dominant Lung Adenocarcinoma.
PubMed 文献 · J Clin Oncol · 2025-07-21

这项多中心、开放标签、III期非劣效随机对照试验在预测无淋巴结转移的磨玻璃影为主型浸润性肺腺癌患者中比较系统纵隔淋巴结清扫与不清扫,中期分析302例显示两组均无淋巴结转移,不清扫组手术时间、出血量和术后住院均显著减少,系统性清扫组出现乳糜胸和术中大出血各1例,结论为应终止试验且不再推荐系统纵隔淋巴结清扫。

要点

  • 中期分析302例中两组均未发现淋巴结转移。
  • 不清扫组手术时间74分钟 vs 清扫组109分钟,P<.001。
  • 不清扫组出血量44 mL vs 清扫组82 mL,P=.033;住院3.9天 vs 4.5天,P=.002。

核心结论

  • 基于中期分析结果和有利原则,试验应终止。
  • 对于磨玻璃影为主型肺腺癌患者,不应再推荐系统纵隔淋巴结清扫。

研究设计与样本

  • 多中心、开放标签、III期、非劣效随机对照试验,比较系统纵隔淋巴结清扫与不清扫纵隔淋巴结。
  • 纳入依据既往试验建立的标准预测无淋巴结转移的磨玻璃影为主型浸润性肺腺癌患者。
  • 主要终点为3年无病生存率。
  • 计划入组300例时进行中期分析,预设终止标准为系统清扫组未检出纵隔淋巴结转移且发生危及生命的并发症。
  • 试验注册于ClinicalTrials.gov(ECTOP-1009,标识符:NCT04527419)。

主要发现

  • 中期分析纳入302例,两个研究组均未发现淋巴结转移。
  • 不清扫组手术时间平均值74分钟 vs 系统清扫组109分钟,P<.001。
  • 不清扫组出血量平均值44 mL vs 系统清扫组82 mL,P=.033。
  • 不清扫组术后住院时间平均值3.9天 vs 系统清扫组4.5天,P=.002。
  • 系统清扫组观察到乳糜胸1例(0.7%)和因上腔静脉损伤致术中大出血1例(0.7%);不清扫组无淋巴结清扫相关并发症。

临床怎么用

  • 原文结论为对于磨玻璃影为主型肺腺癌患者不应再推荐系统纵隔淋巴结清扫。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Systematic mediastinal lymph node dissection (LND) or sampling is currently recommended for patients with early-stage non-small cell lung cancer. We aimed to investigate whether no mediastinal LND was noninferior to systematic LND in patients with ground glass opacity (GGO)-dominant invasive lung adenocarcinoma. METHODS: We conducted a multicenter, open-label, phase III, noninferiority randomized controlled trial comparing systematic mediastinal LND versus no mediastinal LND in patients with GGO-dominant invasive lung adenocarcinoma, who were predicted to have no lymph node metastasis on the basis of criteria established in our previous trial. The primary end point was 3-year disease-free survival. An interim analysis was planned upon enrollment of 300 patients, with predefined termination criteria if no mediastinal lymph node metastasis is detected and life-threatening complications occur in the systematic LND arm. This trial is registered on ClinicalTrials.gov (ECTOP-1009, identifier: NCT04527419). RESULTS: Interim analysis of 302 patients revealed no lymph node metastasis in either study arm. The no LND arm had significantly reduced surgery duration (mean, 74 minutes v 109 minutes; P < .001), blood loss (mean, 44 mL v 82 mL; P = .033), and postoperative hospital stay (mean, 3.9 days v 4.5 days; P = .002). Complications observed in the systematic LND arm included chylothorax in one patient (0.7%) and intraoperative massive bleeding because of superior vena cava injury in one patient (0.7%). No lymphadenectomy-related complications occurred in the no LND arm. CONCLUSION: On the basis of interim findings and the principle of nonmaleficence, the trial should be terminated. Systematic mediastinal LND should no longer be recommended for patients with GGO-dominant lung adenocarcinoma.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Qian B, Song Q, et al. Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity-Dominant Lung Adenocarcinoma. J Clin Oncol. 2025. PMID: 40690727. doi:10.1200/JCO-25-00610

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。